Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search
		×
			NIOSH
			NIOSH
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


The National Institute for Occupational Safety and Health (NIOSH)


Facebook
        Twitter
        LinkedIn
        Syndicate





CRUFOMATE								Related Pages
										*OSHA comments from the January 19, 1989 Final Rule on Air Contaminants Project extracted from 54FR2332 et. seq. This rule was remanded by the U.S. Circuit Court of Appeals and the limits are not currently in force.*
**CAS:** 299-86-5; **Chemical Formula:** C12H19ClNO3P
OSHA had no former limit for crufomate. The ACGIH has a TWA-TLV of 5 mg/m3 and a STEL of 20 mg/m3 for this substance. The proposed PELs were 5 mg/m3 as an 8-hour TWA and 20 mg/m3 as a 15-minute STEL, and NIOSH (Ex. 8-47, Table N1) concurs. The final rule establishes this 8-hour TWA limit but does not establish a STEL for crufomate. Pure crufomate exists as crystals, and commercial crufomate is a yellow oil.
Crufomate actively inhibits both plasma and erythrocyte cholinesterase. A study in humans showed that ingestion of 200 mg of crufomate daily for seven days caused no apparent cholinesterase inhibition in the subjects of this controlled study; however, rats and dogs receiving higher doses (5 mg/kg/day) for two years did show this effect (McCollister, Olson, Rowe et al. 1968/Ex. 1-350).
The American Industrial Hygiene Association (AIHA) testified at the hearing that, in the AIHA’s opinion, OSHA should delete any STELs that the ACGIH has either deleted or indicated that it intends to delete (Ex. 8-16, Tr. p. 3-307). OSHA agrees that such limits should be reevaluated on the basis of current health information (see the discussion in Section VI.C.17); after reviewing the evidence of crufomate’s toxicity in short-term exposures, OSHA has determined that it is not appropriate to include a STEL for this substance in the final rule.
Because cholinesterase inhibition is a very sensitive indicator of exposure, OSHA concludes that the final rule’s 8-hour TWA limit of 5 mg/m3 is needed to provide an appropriate margin of safety below the ingestion NOEL of 200 mg/day for humans, which corresponds approximately to an 8-hour inhalation exposure of 20 mg/m3. The Agency finds that this PEL will protect workers from the significant risk of material health impairment in the form of cholinesterase inhibition, which was possible at the previously uncontrolled levels.
										
							
								Page last reviewed:  September 28, 2011						Content source:  	National Institute for Occupational Safety and Health NIOSH
1988 OSHA PEL Project Documentation
Index of Chemical Names
Index of CAS Numbers Follow NIOSH Facebook
Pinterest
Twitter
YouTube
 NIOSH Homepage NIOSH A-Z
Workplace Safety & Health Topics
Publications and Products
Programs
Contact NIOSH


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue